格列卫国际患者援助项目：内罗毕的经验

The GLIVEC international patient assistance programme: the Nairobi experience.

作者信息

Kiarie G W, Othieno-Abinya N A, Riyat M S

机构信息

Department of Clinical Medicine and Therapeutics, College of Health Sciences, University of Nairobi, P.O. Box 19676-00202, Nairobi, Kenya.

出版信息

East Afr Med J. 2009 Dec;86(12 Suppl):S106-7. doi: 10.4314/eamj.v86i12.62920.

DOI:10.4314/eamj.v86i12.62920

PMID:21591520

Abstract

Glivec is a drug used in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GISI). It is an expensive drug which would be out of reach for most patients in Kenya. Norvatis Pharmaceutical together with Axios International a healthcare management company and Max Foundation have made it possible for patients in developing countries to get access to the drug at no cost. Patients meet the cost of the confirmatory test and are recruited into the programme to receive the drug at no cost. A total of 201 patients are in the programme in Nairobi, mainly drawn from Kenyatta National Hospital the major referral hospital in Kenya. The age range is nine years to 75 years with a mean age of 39.5 years. Males make up 56.5% while females are 43.5%. CML are 173 (86%) while GIST patients are 28 (13.9%). Most of the CML cases are referred in the chronic stable phase (87.8%) and 85.7% have been on hydroxyurea as the initial treatment. Compliance rates are approximately 80%.

摘要

格列卫是一种用于治疗慢性粒细胞白血病（CML）和胃肠道间质瘤（GISI）的药物。它是一种昂贵的药物，肯尼亚的大多数患者都无力承担。诺华制药公司与医疗管理公司Axios International以及马克斯基金会合作，使发展中国家的患者能够免费获得这种药物。患者自行承担确诊测试的费用，并被纳入该项目以免费获得药物。内罗毕共有201名患者参与该项目，主要来自肯尼亚主要的转诊医院肯雅塔国家医院。年龄范围为9岁至75岁，平均年龄为39.5岁。男性占56.5%，女性占43.5%。慢性粒细胞白血病患者有173人（86%），胃肠道间质瘤患者有28人（13.9%）。大多数慢性粒细胞白血病病例在慢性稳定期被转诊（87.8%），85.7%的患者最初接受羟基脲治疗。依从率约为80%。